Investors Alert: Pacira BioSciences Shareholder Class Action Lawsuit Information

Pacira BioSciences Shareholder Alert

A vital notification has been issued for investors in Pacira BioSciences (NASDAQ: PCRX) regarding a class action lawsuit that may impact their interests. ClaimsFiler, a service designed to help shareholders recover from losses, is urging investors who incurred losses exceeding $100,000 while purchasing Pacira securities between August 2, 2023, and August 8, 2024, to take action promptly. The deadline for filing lead plaintiff applications is March 14, 2025.

Background of the Lawsuit

The class action lawsuit claims that Pacira, alongside certain executives, failed to disclose critical information during the specified class period, thereby violating federal securities laws. This has raised concerns among shareholders, particularly as the company's reliance on the Exparel product is significant. The Exparel product represents about 80% of the company's revenue and is under scrutiny due to recent legal developments.

On August 9, 2024, significant news broke regarding the lawsuit against eVenus for patent infringement concerning Exparel. Unfortunately for shareholders, the U.S. District Court for the District of New Jersey ruled that Pacira’s U.S. Patent No. 11,033,495 was declared invalid. This ruling indicated that eVenus was not infringing on the patent, causing a drastic fall in Pacira's share price. The stock plunged by over 47%, dropping from a closing price of $22.36 on August 8, 2024, to a low of $11.70 on the following day. This dramatic decline in share value serves as a primary motivation for shareholders to join the class action.

Legal Support Available

For investors seeking more information or assistance regarding their eligibility for the lawsuit, ClaimsFiler provides a platform where shareholders can access necessary resources to understand their rights and options. Investors are encouraged to visit the dedicated webpage on ClaimsFiler's website at ClaimsFiler.com or call their toll-free hotline at (844) 367-9658. The law firm Kahn Swick & Foti, LLC is available for free consultations to discuss individual legal options and strategies.

This action is currently ongoing in the United States District Court for the District of New Jersey and is officially titled Alvarez v. Pacira BioSciences, Inc., et al., No. 25-cv-00322. As the case progresses, it is essential for affected shareholders to remain engaged and informed.

Why ClaimsFiler Matters

ClaimsFiler operates with a straightforward mission: to provide retail investors with the essential tools and information needed to recover their investments. Offering features such as free registration to access case details, submission of claims, and notifications on relevant cases based on portfolio activities, ClaimsFiler acts as a vital resource for injured investors. As part of its service, investors can also upload transactional data to stay updated on various securities class action cases.

In a financial landscape where class action lawsuits can return significant sums, staying informed and proactive is crucial for any investor affected by these legal proceedings. Investing in understanding your rights and options is the best path forward as this lawsuit unfolds.

In summary, Pacira BioSciences shareholders are encouraged to take immediate action regarding the class action lawsuit to safeguard their investments and potentially recoup losses incurred during the tumultuous period of 2023 and 2024. Don’t wait until the deadline to protect your rights as an investor in a situation that has demonstrated significant volatility and legal challenges.